Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.
RetinalGeniX Technologies Inc. (RTGN) is an innovative ophthalmic research and development company dedicated to advancing the early detection and treatment of ocular diseases. The company focuses on leveraging cutting-edge technology to address systemic diseases like neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions through its pioneering DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software.
RetinalGeniX is at the forefront of developing high-resolution retinal imaging and home monitoring systems that can provide real-time alerts to both physicians and patients. These systems are designed to screen, diagnose, and manage severe eye conditions such as glaucoma, diabetic retinopathy, and macular degeneration, all without the need for pupil dilation.
Recently, RetinalGeniX has made significant strides in remote diagnostic technology, enabling physicians to perform pre-diagnostic assessments of ocular anatomy remotely. This is particularly critical given the global shortage of ophthalmologists and optometrists. As Dr. Jerry Katzman, CEO of RetinalGeniX, emphasizes, early detection through eye screenings can be a game changer in preventing blindness and managing systemic diseases.
The company is also exploring the intersection of genetic markers and high-resolution retinal imaging to aid in the detection and treatment of multiple systemic diseases. They have commenced a study to identify hematology biomarkers that can personalize medical evaluations for patients undergoing treatment for wet macular degeneration, thus potentially reducing costs and improving patient outcomes.
Additionally, RetinalGeniX is developing therapeutic solutions for dry age-related macular degeneration and Alzheimer's syndrome. The company's investigational studies aim to leverage high-resolution retinal imaging and pharmacogenetic mapping to explore new therapies for these chronic diseases.
With a recent patent granted for a device to detect ocular and systemic diseases, RetinalGeniX continues to innovate in affordable, efficient diagnostic technologies. The company's mission is to expand screening capabilities to the masses, thus improving healthcare outcomes globally.
Under the leadership of its experienced team, including interim CFO Virender Ahluwalia, RetinalGeniX is committed to bringing groundbreaking healthcare technologies to market, with the potential to positively impact millions of patients worldwide.
RetinalGenix Technologies (OTCQB:RTGN) has achieved a milestone in developing its high-resolution retinal imaging device and remote monitoring system, successfully imaging patients with its first prototype using both near-infrared and green modes. The device enables secure, real-time 24/7 remote monitoring without requiring pupil dilation or technicians for a 40° field of vision.
The company plans to install units in various healthcare settings and public locations. A specialized network of retinal specialists will be available to review images remotely. The system is designed as a screening tool, not for diagnostic purposes, facilitating immediate resolution through physical examination or prompt doctor visits.
RetinalGenix is also conducting an IRB-approved investigation to correlate genetic markers with intraocular injection success rates for macular degeneration treatment. The company aims to develop a pharmaco-genetic test costing approximately $355 to predict treatment effectiveness. Additionally, RetinalGenix has filed patents in the US and Europe for repurposed FDA-approved pharmaceuticals targeting Dry AMD, diabetic retinopathy, and dementia.
FAQ
What is the market cap of RETINALGENIX TECHNOLOGIES (RTGN)?
What does RetinalGeniX Technologies specialize in?
How does RetinalGeniX's technology help prevent blindness?
What recent advancements has RetinalGeniX made?
Who is leading RetinalGeniX Technologies?
What is the DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software?
What are the company's key therapeutic focuses?
How does RetinalGeniX plan to expand its screening capabilities?
What is the significance of the recent patent granted to RetinalGeniX?
How can physicians benefit from RetinalGeniX's remote diagnostic technology?
What impact could RetinalGeniX's technologies have on global healthcare?
